Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study

Few population-based analyses have investigated survival change in glioblastoma multiforme (GBM) patients treated with concomitant radiotherapy-temozolomide (RT-TMZ) and adjuvant temozolomide (TMZ) and then bevacizumab (BEV) after Food and Drug Administration (FDA) approval, respectively. We aimed t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Ping, Du, Xianglin L., Lu, Guangrong, Zhu, Jay-Jiguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546458/
https://www.ncbi.nlm.nih.gov/pubmed/28467795
http://dx.doi.org/10.18632/oncotarget.17054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546458/
https://www.ncbi.nlm.nih.gov/pubmed/28467795
http://dx.doi.org/10.18632/oncotarget.17054

Ejemplares similares